Assessment of thrombus length in acute ischemic stroke by post-contrast magnetic resonance angiography
- PMID: 29151041
- DOI: 10.1136/neurintsurg-2017-013454
Assessment of thrombus length in acute ischemic stroke by post-contrast magnetic resonance angiography
Abstract
Objectives: Post-contrast magnetic resonance angiography (PC-MRA) enables visualization of vessel segments distal to an intra-arterial thrombus in acute ischemic stroke. We hypothesized that PC-MRA also allows clot length measurement in different intracranial vessels.
Methods: Patients with MRI-confirmed ischemic stroke and intracranial artery occlusion within 24 hours of symptom onset were prospectively evaluated. PC-MRA was added to a standard stroke MRI protocol. Thrombus length was measured on thick slab maximum intensity projection images. Clinical outcome at hospital discharge was assessed by modified Rankin Scale (mRS).
Results: Thirty-four patients (median age 72 years) presenting with a median National Institutes of Health Stroke Scale score of 11 and a median onset to imaging time of 116 min were included. PC-MRA enabled precise depiction of proximal and distal terminus of the thrombus in 31 patients (91%), whereas in three patients (9%) PC-MRA presented a partial occlusion. Median thrombus length in patients with complete occlusion was 9.9 mm. In patients with poor outcome (mRS ≥3) median thrombus length was significantly longer than in those with good outcome (mRS ≤2;P=0.011).
Conclusions: PC-MRA demonstrates intra-arterial thrombus length at different vessel occlusion sites. Longer thrombus length is associated with poor clinical outcome.
Clinical trial registration: NCT02077582; Results.
Keywords: magnetic resonance angiography; mri; stroke.
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Conflict of interest statement
Competing interests: JBF has received consulting, lecture and advisory board fees from Perceptive, BioClinica, Boehringer Ingelheim, Brainomix, Lundbeck and Sygnis. KH reports study grants by Bayer Healthcare, a study grant by Sanofi-Aventis, lecture fees from Bayer Healthcare, Sanofi-Aventis, Pfizer and Bristol-Myers Squibb as well as a consultant relationship with Bayer Healthcare, Pfizer and Edwards Lifesciences. The other authors have no financial disclosures to report.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical